CEO - Nordic Nanovector ; Chairman of the Board - Vivet Therapeutics
With more than twenty-five years’ experience in the biopharmaceutical industry, Eduardo Bravo has a strong track record in leading international biotech and pharmaceutical organizations. He is currently CEO of Nordic Nanovector, a biotech company developing targeted therapies for haematological cancers. Since 2011, as CEO of TiGenix, he successfully developed the company through several financing rounds, led its IPO on NASDAQ, and secured EMA approval of its lead asset. Prior to joining TiGenix’s predecessor, Cellerix, in 2005, he held several senior management positions at Sanofi-Aventis and SmithKline Beecham. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD). He is President of the EBE (European Biopharmaceutical Enterprises) Board of Directors and member of the Executive Committee of ARM (Alliance for Regenerative Medicine).